Myoton AS was established as a spin-out from the University of Tartu, Estonia, with the ambitious goal of pioneering the way muscle health can be quantified. The company has been operating since 1999 and is currently headquartered in Tallinn, Estonia.
The founder and visionary behind the Myoton method is Arved Vain, Doctor of Biology, who has devoted most of his professional career to researching and developing solutions for the assessment of tone and biomechanical properties of skeletal muscles.
Years of R&D have lead the company to the discovery of innovative MyotonPRO technology that holds the promise of becoming the new widely used standard for muscle assessment. The company is in the process of working with several leading clinicians and scientific institutions around the world to conduct a series of validation and feasibility studies of MyotonPRO in a variety of medical applications.
Myoton has received numerous R&D grants from public sector and European Union funding programs, including a €1M EUREKA Eurostars grant and a €250,000 European Space Agency's PECS program grant. In 2008 Myoton raised financing from private investors and initiated the pre-commercialization phase of Myoton technology.
Myoton holds patents in US, EU, Japan and has several new patents pending internationally.